Wall Street brokerages predict that CryoPort Inc (NASDAQ:CYRX) will post earnings per share (EPS) of ($0.07) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for CryoPort’s earnings, with estimates ranging from ($0.08) to ($0.04). CryoPort reported earnings of ($0.12) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 41.7%. The firm is scheduled to announce its next earnings report after the market closes on Tuesday, March 6th.
On average, analysts expect that CryoPort will report full year earnings of ($0.32) per share for the current year, with EPS estimates ranging from ($0.34) to ($0.29). For the next financial year, analysts forecast that the company will report earnings of ($0.23) per share, with EPS estimates ranging from ($0.28) to ($0.18). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that that provide coverage for CryoPort.
Separately, Roth Capital initiated coverage on CryoPort in a report on Thursday, November 30th. They issued a “buy” rating and a $12.50 price target for the company. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. CryoPort presently has an average rating of “Buy” and a consensus target price of $33.50.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Northern Trust Corp increased its holdings in shares of CryoPort by 105.0% in the 2nd quarter. Northern Trust Corp now owns 22,179 shares of the consumer goods maker’s stock valued at $109,000 after acquiring an additional 11,358 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of CryoPort in the 3rd quarter valued at approximately $118,000. US Bancorp DE increased its holdings in shares of CryoPort by 100.9% in the 4th quarter. US Bancorp DE now owns 25,487 shares of the consumer goods maker’s stock valued at $219,000 after acquiring an additional 12,803 shares during the last quarter. Thompson Davis & CO. Inc. increased its holdings in shares of CryoPort by 74.5% in the 4th quarter. Thompson Davis & CO. Inc. now owns 30,100 shares of the consumer goods maker’s stock valued at $259,000 after acquiring an additional 12,850 shares during the last quarter. Finally, Bank of Montreal Can bought a new stake in shares of CryoPort in the 4th quarter valued at approximately $142,000. Institutional investors and hedge funds own 19.78% of the company’s stock.
WARNING: This piece was first published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3223613/0-07-eps-expected-for-cryoport-inc-cyrx-this-quarter.html.
CryoPort Company Profile
Cryoport, Inc (Cryoport) is a provider of cryogenic logistics solutions to the life sciences industry through its purpose-built packaging, information technology and specialized cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.